RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by

N-ацетилцистеин: возможности и перспективы применения при инфекциях мочевыводящих путей

А.А. Гаврусев УО «Белорусский государственный медицинский университет»
DOI:  https://doi.org/10.51922/1818-426X.2024.2.14
2024 №2 | Лекции
Аннотация
Список литературы
Скачать полнотекстовую статью

Представлен обзор литературных данных о перспективах применения ацетилцистеина в терапии инфекций мочевыводящих путей. Кроме известного муколитического эффекта АЦЦ обладает антибактериальными, противовоспалительными и антиоксидантными свойствами. Ряд исследований выявили у АЦЦ способность подавлять развитие бактериальных биопленок, что имеет значение в лечении хронических инфекций, в том числе мочевыводящих путей. Также в исследованиях продемонстрирована противовоспалительная активность АЦЦ, выраженная в снижении выработки интерлейкинов. Представляет интерес свойство АЦЦ подавлять уреазу Proteus mirabilis, одного из основных возбудителей назокомиальной инфекции в урологии. Данное свойство АЦЦ может быть использовано в профилактике инфекции, ассоциированной с мочевыми катетерами и инкрустациями мочеточниковых стентов.

Ключевые слова:
ацетилцистеин (АЦЦ), инфекция мочевыводящих путей (ИМП), бактериальные биопленки, инфекция, ассоциированная с мочевыми кате- терами и стентами
N-acetyl cysteine: possibilities and prospects for use in urinary tract infections

A review of literature data on the prospects for the use of acetylcysteine in the treatment of urinary tract infections is presented. In addition to the well-known mucolytic effect, ACC has antibacterial, anti-inflammatory and antioxidant properties. A number of studies have revealed the ability of ACC to suppress the development of bacterial biofilms, which is important in the treatment of chronic infections, including urinary tract infections. Studies have also demonstrated the anti-inflammatory activity of ACC, expressed in a decrease in the production of interleukins. Of interest is the property of ACC to suppress urease Proteus mirabilis, one of the main causative agents of nasocomial infection in urology. This property of ACC can be used in the prevention of infections associated with urinary catheters and ureteral stents incrustations.

Keywords
N-acetylcysteine (NAC), urinary tract infection (UTI), bacterial biofilms, catheter-associated infections, ureteral stent-associated infections

    1. Hulscher, M. E. J. L., Grol R. P. T. M., Van Der Meer J. W. M. Antibiotic prescribing in hospitals: a social and behavioural scientific approach // Lancet Infect. Dis. – 2010. – Vol. 10, № 3. – P. 167–175.

    2. The multifaceted therapeutic role of N­acetylcysteine (NAC) in disorders characterized by oxidative stress / G. Raghu, M. Berk, P. Campochiaro // Curr Neuropharmacol. – 2021. – Vol. 19, № 8. – P. 1202–1224.

    3. Saddadi, F., Alatab S., Pasha F. The effect of treatment with N­acetylcysteine on the serum levels of C­reactive protein and interleukin­6 in patients on hemodialysis / F. Saddadi, S. Alatab, F. Pasha [et al.] // Saudi J Kidney Dis Transpl. – 2014. – Vol. 25, № 1. – P. 66.

    4. Domenech, M., García E. N­Acetyl­l­Cysteine and Cysteamine as New Strategies against Mixed Biofilms of Nonencapsulated Streptococcus pneumoniae and Non-typeable Haemophilus influenza / M. Domenech, E. García // Antimicrob. Agents Chemother. – 2017. – Vol. 61, № 2. – P. e01992–16.

    5. Zhao, T., Liu Y. N­acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa / T. Zhao, Y. Liu // BMC Microbiol. – 2010. – Vol. 10. – P. 140.

    6. Cammarota, G., Branca G., Ardito F. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial / G. Cammarota, G. Branca, F. Ardito [et al.] // Clin. Gastroenterol. Hepatol. – 2010. – Vol. 8, № 9. – P. 817–820.

    7. Olsson, B., Johansson M., Gabrielsson J. Pharmacokinetics and bioavailability of reduced and oxidized N­acetylcysteine / B. Olsson, M. Johansson, J. Gabrielsson [et al.] // Eur. J. Clin. Pharmacol. – 1988. – Vol. 34. – P. 77–82.

    8. Szkudlarek, U., Zdziechowski A., Witkowski K. Effect of inhaled N­acetylcysteine on hydrogen peroxide exhalation in healthy subjects / U. Szkudlarek, A. Zdziechowski, K. Witkowski // Pulmonary pharmacology & therapeutics. – 2004. – Vol. 17. – P. 155–162.

    9. Сosterton, J. W. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection // Trends Microbiol. – 2001. – Vol. 9, № 2. – P. 50–52.

    10. Перепанова, Т. С. Значение инфекций, обусловленных образованием биопленок, в урологической практике / Т. С. Перепанова // Эффективная фармакотерапия. – 2013. – № 4. – C. 18–27.

    11. Tenke, P., Köves B., Nagy K. Update on biofilm infections in the urinary tract / P. Tenke, B. Köves, K. Nagy [et al.] // World. J. Urol. – 2012. – Vol. 30, № 1. – P. 51–57.

    12. Marchese, A., Bozzolasco M., Gualco L. Effect of fosfomycin alone and in combination with N­acetylcysteine on E. coli biofilms / A. Marchese, M. Bozzolasco, L. Gualco [et al.] // Int. J. Antimicrob. Agents. – 2003. – Vol. 22, suppl. 2. – P. S95–100.

    13. Naves, P., del Prado G., Huelves L., Rodríguez Cerrato V., Ruiz V., Ponte M. C. Effects of human serum albumin, ibuprofen and N­acetyl­L­cysteine against biofilm formation by pathogenic Escherichia coli strains / P. Naves, G. del Prado, L. Huelves, V. Rodríguez­Cerrato, V. Ruiz, M. C. Ponte [et al.] // J. Hosp. Infect. – 2010. – Vol. 76, № 2. – P. 165–70.

    14. Manoharan, A., Ognenovska S., Paino D. N­аcetylcysteine protects bladder epithelial cells from bacterial invasion and displays antibiofilm activity against urinary tract bacterial pathogens / A. Manoharan, S. Ognenovska, D. Paino // Antibiotics. – 2021. – Vol. 10. – P. 900.

    15. Palleschi, G., Carbone A., Zanello P. P. Prospective study to compare antibiosis versus the association of N­acetylcysteine, D­mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation / G. Palleschi, A. Carbone, P. P. Zanello // Archivio Italiano di Urologia e Andrologia. – 2017. – Vol. 89. – P. 1.

    16. Allameh, Z., Karimi A., Tabatabaei, R. S. Effect of N­acetylcysteine on inflammation biomarkers in pediatric acute pyelonephritis: A randomized controlled trial / Z. Allameh, A. Karimi, R. S. Tabatabaei [et al.] // Iran. J. Kidney Dis. – 2015. – Vol. 9. – P. 454–462.

    17. Aslam, S., Darouiche R. O. Role of antibiofilm ­ antimicrobial agents in control of device­related infections / S. Aslam, R. O. Darouiche // Int J Artif Organs. – 2011. – Vol. 34, № 9. – P. 752–758.

    18. El-Feky, M. A., El­Rehewy M. S., Hassan M. A. Effect of ciprofloxacin and N ­acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces / M. A. El­Feky, M. S. El­Rehewy, M. A. Hassan [et al.] // Pol. J. Microbiol. – 2009. – Vol. 58, № 3. – P. 261–7.

    19. Manoharan, A., Farrell J., Aldilla V. R. N­acetylcysteine prevents catheter occlusion and inflammation in catheter associated­urinary tract infections by suppressing urease activity / A. Manoharan, J. Farrell, V. R. Aldilla [et al.] // Front. Cell. Infect. Microbiol. – 2023. – Vol. 13. – P. 1–19.

    20. Hulscher, M. E. J. L., Grol R. P. T. M., Van Der Meer J. W. M. Antibiotic prescribing in hospitals: a social and behavioural scientific approach / M. E. J. L. Hulscher, R. P. T. M. Grol, J. W. M. Van Der Meer // Lancet Infect. Dis. – 2010. – Vol. 10, № 3. – P. 167–175.

    21. The multifaceted therapeutic role of N­acetylcysteine (NAC) in disorders characterized by oxidative stress / G. Raghu, M. Berk, P. Campochiaro // Curr Neuropharmacol. – 2021. – Vol. 19, № 8. – P. 1202–1224.

    22. Saddadi, F., Alatab S., Pasha F. The effect of treatment with N­acetylcysteine on the serum levels of C­reactive protein and interleukin­6 in patients on hemodialysis / F. Saddadi, S. Alatab, F. Pasha [et al.] // Saudi J Kidney Dis Transpl. – 2014. – Vol. 25, № 1. – P. 66.

    23. Domenech, M., García E. N­Acetyl­l­Cysteine and Cysteamine as New Strategies against Mixed Biofilms of Nonencapsulated Streptococcus pneumoniae and Non-typeable Haemophilus influenza / M. Domenech, E. García // Antimicrob. Agents Chemother. – 2017. – Vol. 61, № 2. – P. e 01992–16.

    24. Zhao, T., Liu Y. N­acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa / T. Zhao, Y. Liu // BMC Microbiol. – 2010. – Vol. 10. – P. 140.

    25. Cammarota, G., Branca G., Ardito F. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial / G. Cammarota, G. Branca, F. Ardito [et al.] // Clin. Gastroenterol. Hepatol. – 2010. – Vol. 8, № 9. – P. 817–820.

    26. Olsson, B., Johansson M., Gabrielsson J. Pharmacokinetics and bioavailability of reduced and oxidized N­acetylcysteine / B. Olsson, M. Johansson, J. Gabrielsson [et al.] // Eur. J. Clin. Pharmacol. – 1988. – Vol. 34. – P. 77–82.

    27. Szkudlarek, U., Zdziechowski A., Witkowski K. Effect of inhaled N­acetylcysteine on hydrogen peroxide exhalation in healthy subjects / U. Szkudlarek, A. Zdziechowski, K. Witkowski [et al.] // Pulmonary pharmacology & therapeutics. – 2004. – Vol. 17. – P. 155–162.

    28. Сosterton, J. W. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection / J. W. Сosterton // Trends Microbiol. – 2001. – Vol. 9, № 2. – P. 50–52.

    29. Perepanova, T. S. Znachenie infekcij, obuslovlennyh obrazovaniem bioplenok, v urologicheskoj praktike / T. S. Perepanova // Effektivnaya farmakoterapiya. – 2013. – Vol. 4. – P. 18–27.

    30. Tenke, P., Köves B., Nagy K. Update on biofilm infections in the urinary tract / P. Tenke, B. Köves, K. Nagy [et al.] // World. J. Urol. – 2012. – Vol. 30, № 1. – P. 51–57.

    31. Marchese, A., Bozzolasco M., Gualco L. Effect of fosfomycin alone and in combination with N­acetylcysteine on E. coli biofilms / A. Marchese, M. Bozzolasco, L. Gualco [et al.] // Int. J. Antimicrob. Agents. – 2003. – Vol. 22, Suppl. 2. – P. S95–100.

    32. Naves, P., del Prado G., Huelves L., Rodríguez­Cerrato V., Ruiz V., Ponte M. C. Effects of human serum albumin, ibuprofen and N­acetyl­L­cysteine against biofilm formation by pathogenic Escherichia coli strains / P. Naves, G. del Prado, L. Huelves, V. Rodríguez­Cerrato, V. Ruiz, M. C. Ponte [et al.] // J. Hosp. Infect. – 2010. – Vol. 76, № 2. – P. 165–70.

    33. Manoharan, A., Ognenovska S., Paino D. N­Acetylcysteine protects bladder epithelial cells from bacterial invasion and displays antibiofilm activity against urinary tract bacterial pathogens / A. Manoharan, S. Ognenovska, D. Paino // Antibiotics. – 2021. – Vol. 10. – P. 900.

    34. Palleschi, G., Carbone A., Zanello P. P. Prospective study to compare antibiosis versus the association of N­acetylcysteine, D­mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation / G. Palleschi, A. Carbone, P. P. Zanello // Archivio Italiano di Urologia e Andrologia. – 2017. – Vol. 89. – P. 1.

    35. Allameh, Z., Karimi A., Tabatabaei R. S. Effect of N­acetylcysteine on inflammation biomarkers in pediatric acute pyelonephritis: A randomized controlled trial / Z. Allameh, A. Karimi, R. S. Tabatabaei [et al.] // Iran. J. Kidney Dis. – 2015. – Vol. 9. – P. 454–462.

    36. Aslam, S., Darouiche R. O. Role of antibiofilm ­ antimicrobial agents in control of device­related infections / S. Aslam, R. O. Darouiche // Int J Artif Organs. – 2011. – Vol. 34, № 9. – P. 752–758.

    37. El-Feky, M. A., El­Rehewy M. S., Hassan M. A. et al. Effect of ciprofloxacin and N ­acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces / M. A. El­Feky, M. S. El­Rehewy, M. A. Hassan [et al.] // Pol. J. Microbiol. – 2009. – Vol. 58, № 3. – P. 261–7.

    38. Manoharan, A., Farrell J., Aldilla V. R. N­acetylcysteine prevents catheter occlusion and inflammation in catheter associated­urinary tract infections by suppressing urease activity / A. Manoharan, J. Farrell, V. R. Aldilla [et al.] // Front. Cell. Infect. Microbiol. – 2023. – Vol. 13. – P. 1–19.